April 8, 2024 11:30 AM EDT

AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24

Ryan Cross

Senior Science Correspondent

Lei Lei Wu

News Reporter

SAN DIEGO — AstraZeneca’s experimental PARP1 inhibitor helped shrink tumors in nearly half of people with breast cancers harboring certain DNA repair defects in an early …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24

Ryan Cross

Senior Science Correspondent

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Sanofi introduces new 340B payment model — report

Are programs with compounded GLP-1s safe for your population?

As­traZeneca eyes a safer PARP in­hibitor, with near­ly 50% re­sponse in ad­vanced breast can­cer pa­tients: #AACR24

Senior Science Correspondent

News Reporter

Sign up to read this article for free.

AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24